EBS
Price
$9.88
Change
-$0.09 (-0.90%)
Updated
Jan 17 closing price
Capitalization
120.07M
33 days until earnings call
HROW
Price
$33.84
Change
+$0.38 (+1.14%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
467.85M
54 days until earnings call
Ad is loading...

EBS vs HROW

Header iconEBS vs HROW Comparison
Open Charts EBS vs HROWBanner chart's image
Emergent Biosolutions
Price$9.88
Change-$0.09 (-0.90%)
Volume$872.63K
Capitalization120.07M
Harrow
Price$33.84
Change+$0.38 (+1.14%)
Volume$5.57K
Capitalization467.85M
EBS vs HROW Comparison Chart
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. HROW commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and HROW is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (EBS: $9.97 vs. HROW: $33.46)
Brand notoriety: EBS and HROW are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EBS: 78% vs. HROW: 53%
Market capitalization -- EBS: $120.07M vs. HROW: $467.85M
EBS [@Pharmaceuticals: Other] is valued at $120.07M. HROW’s [@Pharmaceuticals: Other] market capitalization is $467.85M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileHROW’s FA Score has 2 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • HROW’s FA Score: 2 green, 3 red.
According to our system of comparison, HROW is a better buy in the long-term than EBS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 5 TA indicator(s) are bullish while HROW’s TA Score has 4 bullish TA indicator(s).

  • EBS’s TA Score: 5 bullish, 5 bearish.
  • HROW’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, HROW is a better buy in the short-term than EBS.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а -1.19% price change this week, while HROW (@Pharmaceuticals: Other) price change was -7.44% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.37%. For the same industry, the average monthly price growth was +2.59%, and the average quarterly price growth was -9.58%.

Reported Earning Dates

EBS is expected to report earnings on Apr 24, 2025.

HROW is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.37% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HROW($468M) has a higher market cap than EBS($120M). HROW has higher P/E ratio than EBS: HROW (39.53) vs EBS (17.73). EBS YTD gains are higher at: 4.289 vs. HROW (-0.268). HROW has higher annual earnings (EBITDA): 9.95M vs. EBS (-518.2M). EBS has more cash in the bank: 112M vs. HROW (82.8M). HROW has less debt than EBS: HROW (191M) vs EBS (860M). EBS has higher revenues than HROW: EBS (1.02B) vs HROW (130M).
EBSHROWEBS / HROW
Capitalization120M468M26%
EBITDA-518.2M9.95M-5,206%
Gain YTD4.289-0.268-1,599%
P/E Ratio17.7339.5345%
Revenue1.02B130M787%
Total Cash112M82.8M135%
Total Debt860M191M450%
FUNDAMENTALS RATINGS
EBS vs HROW: Fundamental Ratings
EBS
HROW
OUTLOOK RATING
1..100
768
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
10029
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
3637
P/E GROWTH RATING
1..100
1212
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (67) in the Biotechnology industry is in the same range as HROW (88) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (29) in the Pharmaceuticals Other industry is significantly better than the same rating for EBS (100) in the Biotechnology industry. This means that HROW’s stock grew significantly faster than EBS’s over the last 12 months.

EBS's SMR Rating (96) in the Biotechnology industry is in the same range as HROW (97) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to HROW’s over the last 12 months.

EBS's Price Growth Rating (36) in the Biotechnology industry is in the same range as HROW (37) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to HROW’s over the last 12 months.

EBS's P/E Growth Rating (12) in the Biotechnology industry is in the same range as HROW (12) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to HROW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSHROW
RSI
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
81%
Momentum
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
87%
MACD
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 15 days ago
78%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
80%
View a ticker or compare two or three
Ad is loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with HKMPF. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then HKMPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+4.73%
HKMPF - EBS
34%
Loosely correlated
N/A
ZTS - EBS
30%
Poorly correlated
+1.32%
AMRX - EBS
29%
Poorly correlated
+1.09%
HROW - EBS
26%
Poorly correlated
-5.48%
VTRS - EBS
26%
Poorly correlated
-0.44%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMRX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
-5.48%
AMRX - HROW
33%
Loosely correlated
+1.09%
ORGO - HROW
29%
Poorly correlated
+3.10%
RMTI - HROW
26%
Poorly correlated
+0.48%
EBS - HROW
26%
Poorly correlated
+4.73%
AMPH - HROW
25%
Poorly correlated
-1.60%
More